ACM Global Central Lab Platform Now CDISC Compliant
Rochester, NY, Jan. 28, 2010 – ACM Global Central Laboratory, a global central lab, has launched an enhanced version of its proprietary LabStar system, which captures all clinical trial testing data in a single location for easy access and comprehensive reporting. The upgraded system is now completely compliant with the CDISC Laboratory Model, which saves considerable time and effort by standardizing the data capture format. In addition, LabStar features an auto convert function that allows users to toggle between conventional and standard interface (SI) units of report formats as required.
The Web-based platform is available on a global basis. Access is fully secure and compliant with FDA regulations, requiring proper login information for authorized individuals. Users can schedule automatic reports and receive alerts in their email when the reports are accessible. Per-subject reports are available for trial investigators and per-study reports offer sponsor analysis on enrollment status, test result trending and summary data, among many other variables. Furthermore, LabStar’s robust ad hoc reporting enables users to analyze data by any result, demographic or therapeutic detail.
“Serving our customers and providing state of the art solutions is always ACM’s priority; so much so that we formed a customer advisory committee. We value their input and strive to provide optimal solutions,” said Elena Logan, VP of Clinical Trials, ACM Global Central Lab. “We are excited to offer our clients a much more flexible, highly intuitive solution that allows them access to their lab data.”
LabStar is a value-added service that empowers users to achieve optimum protocol efficiency. Closing managing and monitoring a protocol can save time and money by making decisions with real-time results. LabStar data is in strict accordance with GCP and HIPPA regulations and now enables convenient feedback to ACM for training requests, technical issues or suggestions for continual improvement.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.
